NVO - HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside

2024-07-19 10:59:42 ET

Summary

• By 2030, the weight loss drug market is estimated to reach a significant size, attracting many competitors due to the high prevalence of obesity-related comorbidities.
• The Tema Obesity & Cardiometabolic ETF offers exposure to leading biotech and pharma companies in the anti-obesity drugs market, focusing on GLP-1 medicines.
• HRTS outperformed the market since its inception, with a focus on mid-cap pharma businesses and a moderate risk profile, making it a favorable investment in the expanding cardiometabolic drugs market.

According to the Centers for Disease Control ((CDC)), approximately 42% of people in the U.S. are afflicted with obesity, and 9.2% of the population meet the criteria for severe obesity. Therefore, it's no surprise why Goldman Sachs Research isn't alone in estimating that by 2030, the market for weight loss drugs will reach a size of around $100 billion . Such a vast market will doubtlessly support many competitors. The myriad comorbidities of obesity, including type 2 diabetes and cardiovascular disease in particular, guarantee the presence of many different medical niches to be served with specialized therapies. And that's before even getting into the massive swath of the market that's likely to be servable with generalist weight loss drugs....

For further details see: